SalaryGuide
AboutPricingFor Employers

Marketing jobs

6 marketing jobs

Teva Pharmaceuticals logo
5 weeks ago

Director, CRM & Marketing Technology Strategy

Teva Pharmaceuticals

Parsippany, NJ (On-site)Full time$161K/yr – $202K/yr
Teva Pharmaceuticals logo
6 weeks ago

Sr Manager, Non-Traditional Generics Marketing

Teva Pharmaceuticals

Parsippany, NJ (Hybrid)Full time$133K/yr – $166K/yr
Teva Pharmaceuticals logo
6 weeks ago

Associate Director Marketing, HCP Medical Education

Teva Pharmaceuticals

Parsippany, NJ (On-site)Full time$154K/yr – $202K/yr
Teva Pharmaceuticals logo
6 weeks ago

Director UZEDY Marketing HCP Promotion

Teva Pharmaceuticals

Parsippany, NJ (On-site)Full time$182K/yr – $239K/yr
Teva Pharmaceuticals logo
2 months ago

Director, Marketing - Launch Lead

Teva Pharmaceuticals

New Jersey, USA (Unknown)$182K/yr – $239K/yr
Teva Pharmaceuticals logo
5 months ago

Director, Omnichannel Marketing

Teva Pharmaceuticals

Southwest Ranches, FL (On-site)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

6 jobs
Teva Pharmaceuticals logo

Director, CRM & Marketing Technology Strategy

Teva Pharmaceuticals

Parsippany, NJ (On-site)

$161K/yr - $202K/yrIn-houseFull-timeDirector/executive10+ years exp.
5 weeks ago
Teva Pharmaceuticals logo

Sr Manager, Non-Traditional Generics Marketing

Teva Pharmaceuticals

Parsippany, NJ (Hybrid)

$133K/yr - $166K/yrIn-houseFull-timeSenior level5+ years exp.
6 weeks ago
Teva Pharmaceuticals logo

Associate Director Marketing, HCP Medical Education

Teva Pharmaceuticals

Parsippany, NJ (On-site)

$154K/yr - $202K/yrIn-houseFull-timeManager7+ years exp.
6 weeks ago
Teva Pharmaceuticals logo

Director UZEDY Marketing HCP Promotion

Teva Pharmaceuticals

Parsippany, NJ (On-site)

$182K/yr - $239K/yrIn-houseFull-timeDirector/executive10+ years exp.
6 weeks ago
Teva Pharmaceuticals logo

Director, Marketing - Launch Lead

Teva Pharmaceuticals

New Jersey, USA (Unknown)

$182K/yr - $239K/yrIn-houseDirector/executive10+ years exp.
2 months ago
Teva Pharmaceuticals logo

Director, Omnichannel Marketing

Teva Pharmaceuticals

Southwest Ranches, FL (On-site)

In-houseFull-timeDirector/executive8+ years exp.
5 months ago
Teva Pharmaceuticals logo
Teva Pharmaceuticals

Director, CRM & Marketing Technology Strategy

Parsippany, NJ (On-site)

$161K/yr – $202K/yrDirector/Executive10+ years expFull time

Posted 5 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and drive the CRM and Marketing Technology strategy across Veeva, Salesforce, and MarTech, aligning with brand and field plans, while leading data integration, analytics enablement, and omnichannel campaigns.

  • Own CRM/MarTech roadmap and platform architecture including Veeva, Salesforce, and CDP/ID resolution.
  • Lead cross-functional collaboration with Marketing, Sales, and Digital Engagement to enable data-driven campaigns and field enablement.

Job Description

Responsibilities

  • Strategic Leadership & Roadmap Ownership
  • Define and execute the CRM & Marketing Technology strategy aligned with Commercial brand plans, field engagement strategies, and digital transformation goals.
  • Serve as a strategic advisor to Marketing, Sales, Market Access, and Digital Engagement leaders.
  • Continuously evaluate market trends, emerging technologies, and customer expectations to shape future capabilities.
  • CRM Platform Ownership (Veeva & Salesforce)
  • Own the strategy, architecture, and enhancement roadmap for Veeva CRM, including MyInsights, CLM, Events Management, and approved email.
  • Oversee Salesforce capabilities (Salesforce CRM, Marketing Cloud/Pardot, Experience Cloud) to support omnichannel and field enablement needs.
  • Ensure seamless integration across CRM, MDM, data platforms, digital channels, and analytics tools.
  • Drive field usability, data quality, and optimized workflows to enhance engagement effectiveness.
  • Marketing Technology (MarTech) & Omnichannel Enablement

Requirements

  • 10+ years in CRM, MarTech, Digital, or Commercial IT roles, preferably within pharmaceutical or life sciences.
  • Bachelor’s Degree
  • Deep hands-on experience with Veeva CRM, Salesforce (CRM, Marketing Cloud), Veeva Vault PromoMats, and Informatica for integration and data management.
  • Strong understanding of Commercial processes—omnichannel engagement, digital campaigns, field enablement, content activation, data flows, and analytics.
  • Proven ability to build and deliver complex CRM/MarTech capabilities in matrixed environments.
  • Experience leading technical teams, agencies, and platform vendors.

Preferred

  • Experience with innovative, specialty, or rare-disease drug launches.
  • Knowledge of CDP technologies, identity resolution, and AI/ML marketing tools.
  • Master’s degree in Information Systems, Marketing Technology, Computer Science, or a related field.

Benefits

  • At Teva, better health starts from within, and that includes you. From day one, you’ll be supported with benefits designed to help you thrive in and out of work. This includes generous annual leave, reward plans, flexible working schedules (dependent on role), access to tailored health support, and meaningful ways to give back to the community.  When it comes to your career, you’ll be encouraged to explore, evolve, and shape your path. Twist, our one-stop shop for career development platform, gives you access to a wide range of possibilities, from learning programs and short-term projects to opportunities for internal growth. Here, you’ll be part of a culture that empowers you to reach your goals and prioritize your wellbeing every step of the way.
  • Make sure to apply through our internal career site on Twist—your one-stop shop for career development
Teva Pharmaceuticals logo

Teva Pharmaceuticals

3.6 Glassdoor

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Founded in 1901
Tel Aviv-Yafo, Tel Aviv District, ISR
30K employees (1,056 in marketing)
www.tevapharm.com
70% recommend to a friend
82% CEO approval

Traffic Signals

Monthly Visitors
115.6K
Traffic Source Mix
Search
54.6%
Direct
32.5%
Referral
8.7%
Social
2.2%
Paid
1.1%

Headcount Trend

Current headcount: ~30K

Marketing Team

Marketing Team Size
826 (3% of company)
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$5.5B
Last Raise
$400M
Post IPO Equity, 2 months ago

Funding History

  • Mar 2026
    Post IPO Equity • $400M
  • Jan 2026
    Post IPO Equity • $500M
  • May 2025
    Post IPO Debt • $2.3B

Recent News

Should We Be Cautious About Teva Pharmaceutical Industries Limited's (NYSE:TEVA) ROE Of 9.1%?
Dec 5, 2025 • Yahoo Finance
Teva seeks startups to help solve global pharmaceutical challenges
Nov 19, 2025 • Reuters
Teva calls on startups to Rise to the occasion with open innovation platform for 7 biopharma challenges
Nov 19, 2025 • Fierce Pharma
We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative
Nov 13, 2025 • simplywall.st
Teva Pharma stock hits 52-week high at $25.96
Nov 13, 2025 • Investing.com
We Like The Quality Of Teva Pharmaceutical Industries' (NYSE:TEVA) Earnings
Nov 12, 2025 • Yahoo Finance
Teva Hits Profit-Taking Zone On Austedo's Big Sales Beat
Nov 5, 2025 • Investor's Business Daily
Teva CEO touts 'defining strength' of innovative drugs as its sales grow for 11th straight quarter
Nov 5, 2025 • Fierce Pharma
Teva Pharmaceutical Industries Ltd reports results for the quarter ended September 30 - Earnings Summary
Nov 5, 2025 • TradingView
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth ...
Nov 5, 2025 • Yahoo Finance
Earnings call transcript: Teva beats Q3 2025 forecasts, stock surges
Nov 5, 2025 • Investing.com
Why Teva Pharmaceutical Stock Rocked the Market Today
Nov 5, 2025 • The Motley Fool
Teva shares soar on strong third-quarter performance
Nov 5, 2025 • CTech
Teva Pharm profit tops estimates, says not worried by US tariffs
Nov 5, 2025 • Reuters
Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Nov 4, 2025 • Yahoo Finance
Is Teva a Value Opportunity After Recent 8.1% Share Price Jump?
Nov 2, 2025 • simplywall.st
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation: Is There Untapped Value After Recent Uptrend?
Oct 30, 2025 • Yahoo Finance
Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe
Oct 24, 2025 • Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Oct 22, 2025 • Yahoo Finance
Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?
Oct 21, 2025 • Yahoo Finance
JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)
Oct 20, 2025 • Yahoo Finance
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
Oct 16, 2025 • Yahoo Finance
BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid “Pivot to Growth” Strategy Execution
Oct 13, 2025 • Yahoo Finance
Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside (NYSE:TEVA)
Oct 7, 2025 • Seeking Alpha
Teva closes in on sale of API business TAPI
Oct 2, 2025 • European Pharmaceutical Review
UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00
Oct 1, 2025 • Yahoo Finance
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Sep 30, 2025 • Nasdaq
JHX SHAREHOLDER ALERT: James Hardie Industries plc Investors may have been Affected by Fraud -- Contact BFA Law about its Investigation
Sep 26, 2025 • Bleichmar Fonti & Auld
TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight
Sep 25, 2025 • PR Newswire UK
TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight
Sep 25, 2025 • PR Newswire
Teva Releases Q3 2025 Aide Memoire
Sep 25, 2025 • BioSpace
Teva Releases Q3 2025 Aide Memoire
Sep 25, 2025 • Teva Pharmaceutical Industries Ltd
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
Sep 25, 2025 • Teva Pharmaceutical Industries Ltd
Teva Pharma stock price target raised to $26 by UBS on Austedo outlook
Sep 24, 2025 • Investing.com
Enery signs 15-year PPA with Teva Bulgaria | Bulgaria Investments News
Sep 24, 2025 • SeeNews
Truist Securities reiterates Buy rating on Teva Pharma stock, maintains $25 price target
Sep 23, 2025 • Investing.com
Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
Sep 23, 2025 • PharmiWeb
Bausch Health, Teva Hit With Xifaxan Pay-for-Delay Scheme Claims
Sep 23, 2025 • bloomberglaw.com
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Sep 22, 2025 • BioSpace
Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation Potential After Recent Share Movement
Sep 21, 2025 • Yahoo Finance
Teva preesents 10 posters from its schizophrenia medicines portfolio
Sep 21, 2025 • thefly.com
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Sep 21, 2025 • thecanadianpressnews.ca
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Sep 21, 2025 • MarketScreener
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Sep 21, 2025 • Teva Pharmaceutical Industries Ltd
Roche to buy 89bio for up to $3.5b
Sep 18, 2025 • Globes
Teva’s SWOT analysis: pharma giant’s stock pivots to growth amid challenges
Sep 17, 2025 • Investing.com
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Sep 17, 2025 • BioSpace
Teva Pharmaceutical Industries (TEVA) Attains FDA’s Fast Track Designation for Emrusolmin
Sep 16, 2025 • Yahoo Finance
FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters
Sep 16, 2025 • FiercePharma
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Sep 16, 2025 • Teva Pharmaceutical Industries Ltd
Belgian investors unknowingly back Israeli firms through bank funds
Sep 15, 2025 • belganewsagency.eu
J.P. Morgan Maintains a Buy on Teva Pharmaceutical (TEVA) With a $23 PT
Sep 11, 2025 • Yahoo Finance
Teva at Morgan Stanley Conference: Pivot to Growth Strategy
Sep 9, 2025 • Investing.com
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
Sep 9, 2025 • GlobeNewswire
Teva Pharmaceutical Says US FDA Grants Emrusolmin Fast Track Designation for Multiple System Atrophy Treatment
Sep 9, 2025 • MarketScreener
WHO Adds GLP-1s to List of Essential Medicines
Sep 8, 2025 • BioSpace
Pro-Palestine protesters in Ireland, Northern Ireland call for boycott of Israeli goods
Sep 6, 2025 • Arab News
Medincell: Reminder of the Participation Terms in the Combined General Meeting
Sep 3, 2025 • PharmiWeb
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
Sep 2, 2025 • Teva Pharmaceutical Industries Ltd
Teva wins FDA approval for first generic weight loss GLP-1
Sep 1, 2025 • BioXconomy
Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda
Aug 30, 2025 • Yahoo Finance
Teva wins US obesity approval for its GLP-1 generic liraglutide
Aug 29, 2025 • European Pharmaceutical Review
Seminar: IP That Matters - Behind Orexo’s Milestone Patent Win at the US Court
Aug 29, 2025 • News Powered by Cision
US FDA approves Teva Pharmaceuticals' generic obesity drug
Aug 28, 2025 • Reuters
With Saxenda generic, Teva launches first copycat GLP-1 for obesity
Aug 28, 2025 • Fierce Pharma
US FDA approves Teva Pharmaceuticals' generic obesity drug
Aug 28, 2025 • Reuters
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda
Aug 28, 2025 • Benzinga.com
The Chip on America's Shoulder
Aug 28, 2025 • MarketScreener
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
Aug 28, 2025 • Teva Pharmaceutical Industries Ltd
Teva stock rises on launch of first generic weight loss GLP-1 drug
Aug 28, 2025 • Investing.com
Healthcare workers across Italy to hold hunger strike protest in solidarity with Gaza
Aug 27, 2025 • Wanted in Rome - News in Italy - Rome's local English news
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Aug 26, 2025 • Morningstar.com
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 26, 2025 • BioSpace
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 25, 2025 • Business Wire
Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)
Aug 25, 2025 • Yahoo Finance
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Aug 25, 2025 • Catalyst Pharmaceuticals, Inc.
US Narcolepsy Drugs Market Outlook and Company Analysis Report 2025-2033 Featuring Jazz Pharma, Ligand Pharma, Novartis, Takeda Pharma, Teva, Hikma, Harmony Biosciences, Roche - ResearchAndMarkets.com
Aug 25, 2025 • Business Wire
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Aug 25, 2025 • MarketScreener
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 25, 2025 • PharmiWeb
Stanley Druckenmiller builds Teva position. - Globes
Aug 24, 2025 • Globes - Israel Business News
Children’s Health Ireland demands end use Teva medication
Aug 23, 2025 • The Jerusalem Post
Biosimilars Market to Surpass US$ 171.79 Billion by 2033 - Exclusive Report by DataM Intelligence
Aug 22, 2025 • PR Newswire UK
Teva Pharmaceuticals’ Market Shift: Growth or Mirage?
Aug 21, 2025 • StocksToTrade
Deoxyribonucleic Acid (DNA) Repair Alkylating Agent Market to Reach US $5.05 Billion by 2029
Aug 21, 2025 • EIN Presswire
Outrage in Italy after medical staff seen discarding Israeli-made Teva medications
Aug 20, 2025 • Ynetnews
Common Cold Market to Reach $34.3 Billion by 2029 with 6.2% CAGR
Aug 20, 2025 • EIN Presswire
Fda says Teva Pharmaceuticals USA discontinues manufacture of Finasteride tablet, 5 mg
Aug 19, 2025 • MarketScreener
Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue
Aug 18, 2025 • Investing.com
Global Women’s Health Market to Grow at 4–5% CAGR Driven by Disease Burden and Contraceptive Demand by 2030
Aug 18, 2025 • PharmiWeb
Teva Pharmaceuticals USA discontinues manufacturing of celecoxib, capsule, says FDA
Aug 15, 2025 • MarketScreener
2025 Q2 Job Market Report: Quartlery Job Postings Decline for Third Straight Quarter
Aug 15, 2025 • BioSpace
Vitamin B12 Market Set to Surpass USD 444.47 Million by 2030, Driven by Rising Veganism, Preventive Healthcare Focus, and Growth in Nutraceuticals: MarkNtel Advisors
Aug 14, 2025 • PR Newswire
Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth
Aug 14, 2025 • Research and Markets
United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis
Aug 14, 2025 • Research and Markets
Senores Pharma to buy two ANDAs from Teva, its third US transaction this year
Aug 13, 2025 • Hindu Business Line
FDA approves AJOVY for paediatric migraine prevention
Aug 13, 2025 • Pharma Times
Cancer Pain Market Forecast to Hit US $10.32 billion by 2030 on Rising Demand & Cannabis-Driven Therapies
Aug 13, 2025 • EIN Presswire
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
Aug 13, 2025 • Research and Markets
Intelligent Asthma Monitoring Devices to Reach US $1.69 Bn by 2030 as AI-Driven Platforms Enhance Early Detection
Aug 13, 2025 • EIN Presswire
Triamterene Capsules Market set to hit $1437.5 million by 2035
Aug 12, 2025 • PRLog